Towards Healthcare
U.S. Immunoassay Market Surges USD 9.43 Bn in 2025

U.S. Immunoassay Market Transformation with AI Adoption

Projections indicate that, the U.S. immunoassay market will increase from USD 8.99 billion in 2024 to USD 14.22 billion by 2034, experiencing a CAGR of 4.93% over the next 10 years. The expansion of immunoassays in the U.S. goes beyond traditional diagnostics into areas like therapeutic drug monitoring, personalized medicine, and biomarker discovery.

  • Insight Code: 6171
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The U.S. immunoassay market stands at USD 9.43 billion in 2025 and is expected to reach USD 14.22 billion by 2034, growing at a CAGR of 4.93% from 2024 to 2034.

The U.S. immunoassay market includes six segments such as product, technology, application, end-use, and specimen.

Key trends include point-of-care testing, non-invasive testing, at-home diagnostics, automation, companion diagnostics, biomarker-based immunoassays, etc.

National Institutes of Health, FDA, WHO, HHS, NIST, BARDA.